1. Scrip
  2. >>Archive

Perrigo CEO defends Elan acquisition

 
• By Sukaina Virji

When news of Perrigo's friendly acquisition offer for Elan hit the news wires on the morning of 29 July, the over-riding reaction from observers was one of confusion. Why was this a good deal for Perrigo? Surely it could have taken advantage of the Irish tax system through the more cheaper option of relocating domicile to Ireland, just as Shire did a few years ago, rather than paying out cash and stock of $8.6bn (scripintelligence.com, 29 July 2013)?

When news of Perrigo's friendly acquisition offer for Elan hit the news wires on the morning of 29 July, the over-riding reaction from observers was one of confusion. Why was this a good deal for Perrigo? Surely it could have taken advantage of the Irish tax system through the more cheaper option of relocating domicile to Ireland, just as Shire did a few years ago, rather than paying out cash and stock of $8.6bn (scripintelligence.com, 29 July 2013)?

In a conference call later in the day, Perrigo's CEO Joseph Papa presented his rationale for the transaction. However, the...

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By Mandy Jackson

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.